Emerging strategies for pegylated interferon combination therapy

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue SUPPL. 1, 2007, Pages

  Schiff, Eugene R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; HCV 796; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; PEGINTERFERON; PEGINTERFERON ALPHA2B; POLYMERASE INHIBITOR; PROTEINASE INHIBITOR; R 1626; RIBAMIDINE; RIBAVIRIN; RITONAVIR; SCH 503034; TARIBAVIRIN; UNCLASSIFIED DRUG; VALOPICITABINE; VIRUS RNA; VX 950; XLT 2125;

ANEMIA; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; VIRUS CULTURE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RIBAVIRIN; VIRAL VACCINES; VIRUS REPLICATION;

EID: 33846410735     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0691     Document Type: Article

References (16)

1. Zhong J et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294-9299
2. Wakita T et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796
3. Lindenbach BD et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623-626
4. Gish RG et al. (2004) End-of-treatment (EOT) response in therapy-naïve patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a. Hepatology 40 (Suppl 1): 519A
5. Benhamou Y et al. (2006) The safety and efficacy of Viramidine® plus pegylated interferon alfa-2b versus ribavirin plus pegylated interferon alfa-2b in therapy-naïve patients infected with HCV: Phase 3 results [abstract #751]. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver: 2006 April 26-30; Vienna, Austria
6. Reesink HW et al. (2005) Initial results of a phase 1B, multiple dose study of VX-950, a hepatitis C virus protease inhibitor. Gastroenterology 128 (Suppl): A-697
7. Reesink HW et al. (2005) Final results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 42 (Suppl 1): 234A-235A
8. Vertex Pharmaceuticals Incorporated (2006) Vertex successfully completes key studies with VX-950 to prepare for next steps in clinical program [http://www.vpharm.com/Pressreleases2006/pr020706.html] (accessed July 7 2006)
9. Lawitz EJ et al. (2006) 28 days of the hepatitis C protease C inhibitor VX-950, in combination with peginterferon-alfa-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects [abstract #686f]. Gastroenterology 131: 950-951
10. Zeuzem S et al. (2005) Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-α). Hepatology 42: 233A
11. Malcolm BA (2005) Modeling of hepatitis C viral dynamics during combination therapy with peginterferon alfa-2B (peg-intron) and the NS3 protease inhibitor SCH 503034 [abstract #1266]. Presented at the Annual Meeting of the American Association for the Study of Liver Disease: 2005 November 11-15; San Francisco, CA
12. Foy E et al. (2005) Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 102: 2986-2991
13. Kempf DJ et al. (2006) Pharmacokinetic boosting of VX-950, an inhibitor of HCV protease, by co-dosing with ritanovir [abstract #4]. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver: April 26-30; Vienna, Austria
14. Rodriguez-Torres M (2005) Valopicitabine (nm283) alone and in combination with peg-interferon in patients with genotype 1 chronic hepatitis C: Preliminary results from an ongoing phase II, multicenter study. Gastroenterology 128 (Suppl): A-695
15. Tomei L et al. (2005) HCV antiviral resistance: The impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antivir Chem Chemother 16: 225-245
16. Viral Hepatitis Resource Center [http://www.cdc.gov/ncidod/diseases/ hepatitis/resource/index.htm] (accessed October 2 2006)